1. Name Of The Medicinal Product
Vermox 100 mg tablets
2. Qualitative And Quantitative Composition
Each tablet contains 100 mg of mebendazole.
Excipients: Each tablet also contains 0.06 mg of sunset yellow (E110).
For a full list of excipients, see section 6.1
3. Pharmaceutical Form
Tablet.
Flat, circular, pale orange tablets with “Me/100” on one side and “JANSSEN” on the other.
4. Clinical Particulars
4.1 Therapeutic Indications
For the treatment of Trichuris trichuria (whipworm), Enterobius vermicularis (pinworm or threadworm), Ascaris lumbricoides (roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed gastrointestinal infestations.
There is no evidence that Vermox Tablets are effective in the treatment of cysticercosis.
4.2 Posology And Method Of Administration
Adults and children over 2 years:
For the control of trichuriasis, ascariasis and hookworm infections, one tablet twice a day for three consecutive days.
For the control of enterobiasis a single tablet is administered. It is highly recommended that a second tablet is taken after two weeks, if re-infection is suspected.
Tablets may be chewed or swallowed whole. Crush the tablet before giving it to a young child. Always supervise a child while they are taking this medicine.
Method of Administration
Oral use.
4.3 Contraindications
Vermox is contraindicated in pregnancy and in patients who have shown hypersensitivity to the product or any components.
4.4 Special Warnings And Precautions For Use
Not recommended in the treatment of children under 2 years.
A case-control study of a single outbreak of Stevens-Johnson syndrome /toxic epidermal necrolysis (SJS/TEN) suggested a possible association with the concomitant use of metronidazole with mebendazole. Although there are no additional data on this potential interaction, concomitant use of mebendazole and metronidazole should be avoided.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Concomitant treatment with cimetidine may inhibit the metabolism of mebendazole in the liver, resulting in increased plasma concentrations of the drug.
Concomitant use of mebendazole and metronidazole should be avoided (see section 4.4).
4.6 Pregnancy And Lactation
Since Vermox is contra-indicated in pregnancy, patients who think they are, or may be, pregnant should not take this preparation.
Lactation
As it is not known whether mebendazole is excreted in human milk, it is not advisable to breast feed following administration of Vermox.
4.7 Effects On Ability To Drive And Use Machines
Vermox has no influence on the ability to drive and use machines.
4.8 Undesirable Effects
Throughout this section adverse reactions are reported. Adverse reactions are adverse events that were considered to be reasonably associated with the use of Vermox based on the comprehensive assessment of the available adverse event information. A causal relationship with Vermox cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of Vermox was evaluated in 6276 subjects who participated in 39 clinical trials for the treatment of single or mixed parasitic infestations of the gastrointestinal tract. In these 39 clinical trials, no adverse drug reactions (ADRs) occurred in
ADRs identified from clinical trials and post-marketing experience with Vermox are included in Table 1. The displayed frequency categories use the following convention:
Very common (
Table 1: Adverse Drug Reactions Reported in Clinical Trials and Post-marketing Experience for Vermox
|
| ||
| |||
|
|
| |
|
| ||
|
| ||
|
| ||
|
|
| |
|
| ||
|
|
a ADR frequency data derived from Clinical Trials or Epidemiological Studies
b ADRs not observed in clinical trials and frequency calculated using “Rule of 3”, as detailed in SmPC guideline 2009. 6276 patients exposed in clinical trials and epidemiological studies, divided by 3 (Frequency = 1/2092). Note: frequencies differ from those reported in the August 2009 CCDS, as these were not calculated using the formula detailed in the SmPC guideline 2009.
4.9 Overdose
In patients treated at dosages substantially higher than recommended or for prolonged periods of time, the following adverse reactions have been reported rarely: alopecia, reversible liver function disturbances, hepatitis, agranulocytosis, neutropenia and glomerulonephritis. With the exception of agranulocytosis and glomerulonephritis, these also have been reported in patients who were treated with mebendazole at standard dosages (see section 4.8).
Symptoms
In the event of accidental overdosage, abdominal cramps, nausea, vomiting and diarrhoea may occur.
Treatment
There is no specific antidote. Within the first hour after ingestion, gastric lavage may be performed. Activated charcoal may be given if considered appropriate.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: anthelmintic for oral administration, benzimidazole derivatives; ATC code: P02CA01.
In vitro and in vivo work suggests that mebendazole blocks the uptake of glucose by adult and larval forms of helminths, in a selective and irreversible manner. Inhibition of glucose uptake appears to lead to endogenous depletion of glycogen stores within the helminth. Lack of glycogen leads to decreased formation of ATP and ultrastructural changes in the cells.
There is no evidence that Vermox is effective in the treatment of cysticercosis.
5.2 Pharmacokinetic Properties
Using a tracer dose of 3H-mebendazole, the pharmacokinetics and bioavailability of a solution and IV drug have been examined. After oral administration, the half life was 0.93 hours. Absorption of this tracer dose was almost complete but low availability indicated a high first pass effect. At normal therapeutic doses, it is very hard to measure levels in the plasma.
5.3 Preclinical Safety Data
No relevant information additional to that contained elsewhere in the Summary of Product Characteristics.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Microcrystalline cellulose
Sodium starch glycolate
Talc
Maize starch
Sodium saccharin
Magnesium stearate
Cottonseed oil hydrogenated
Orange flavour
Colloidal anhydrous silica
Sodium lauril sulfate
Sunset yellow (E110)Purified water*
2-propanol*
* Not present in the final product.
6.2 Incompatibilities
Not applicable.
6.3 Shelf Life
3 years.
6.4 Special Precautions For Storage
This medicinal product does not require any special storage conditions. .
6.5 Nature And Contents Of Container
Blister strips of PVC genotherm glass clear aluminium foil coated on the inside with a heat seal lacquer.
Pack sizes: 1 and 6 tablet packs.
Not all pack sizes may be marketed.
6.6 Special Precautions For Disposal And Other Handling
No special requirements.
7. Marketing Authorisation Holder
Janssen-Cilag Ltd
50-100 Holmers Farm Way
High Wycombe
Buckinghamshire
HP12 4EG
UK
8. Marketing Authorisation Number(S)
PL 00242/0011
9. Date Of First Authorisation/Renewal Of The Authorisation
Date of First Authorisation: 9 April 1975
Date of Renewal of Authorisation: 30 September 2003
10. Date Of Revision Of The Text
24/03/2011
LEGAL CATEGORY
POM
